Research programme: steroid 11-beta- hydroxylase inhibitors - ElexoPharm

Drug Profile

Research programme: steroid 11-beta- hydroxylase inhibitors - ElexoPharm

Alternative Names: CYP11B1 inhibitors - ElexoPharm

Latest Information Update: 19 Jul 2016

Price : $50

At a glance

  • Originator ElexoPharm GmbH
  • Class
  • Mechanism of Action Steroid 11-beta-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cushing syndrome

Most Recent Events

  • 19 Jul 2016 Preclinical trials in Cushing's syndrome in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top